In what may prove to be a major step forward for the treatment of HIV-1 infection, scientists have discovered an effective way to eliminate a notoriously persistent form of the virus that does not respond to current therapies. The research, published online by Cell Press on March 8th from the journal Immunity, describes a vaccination strategy that may be essential for successful eradication efforts and should therefore be considered for future clinical trials.
Current antiretroviral therapies suppress the ability of HIV-1 to copy itself, but they cannot completely eliminate the virus. Under these treatment conditions, HIV-1 enters a silent, or "latent", state that rapidly becomes active again as soon therapy is stopped. "Because of the stability of latent HIV-1 inside of infected T cells, lifelong antiretroviral therapy is required, raising concerns about adverse affects over decades of therapy, the evolution of resistance, and the financial burden of treatment," explains senior study author, Dr. Robert F. Siliciano, from the Johns Hopkins University School of Medicine. "Therefore, there is an urgent need for strategies to eradicate HIV-1 from infected individuals."
Previous research has suggested that reactivation of the latent HIV-1 is an important first step for complete elimination of the virus, but it is not clear whether the activated virus or the host immune response will then lead to elimination of the infected cells. In the current study, Siliciano and colleagues observed that infected T cells survived after the latent virus was reactivated. However, when the immune response of the host T cells was heightened before the virus was reactivated, the infected cells were efficiently eliminated.
"Our results suggest that reactivation of latent HIV-1 will not purge the latent viral reservoir and that stimulation of HIV-1-specific T cell responses prior to virus reactivation may be essential for viral eradication," concludes Siliciano. "Therefore, an appropriately timed vaccination that boosts the response of the immune system to HIV-1 may be critical for therapies that move beyond suppression of HIV-1 to true elimination."
I Was There: An Infection Preventionist on the COVID-19 Pandemic
April 30th 2025Deep feelings run strong about the COVID-19 pandemic, and some beautiful art has come out of those emotions. Infection Control Today is proud to share this poem by Carmen Duke, MPH, CIC, in response to a recent article by Heather Stoltzfus, MPH, RN, CIC.
From the Derby to the Decontam Room: Leadership Lessons for Sterile Processing
April 27th 2025Elizabeth (Betty) Casey, MSN, RN, CNOR, CRCST, CHL, is the SVP of Operations and Chief Nursing Officer at Surgical Solutions in Overland, Kansas. This SPD leader reframes preparation, unpredictability, and teamwork by comparing surgical services to the Kentucky Derby to reenergize sterile processing professionals and inspire systemic change.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.